<?xml version="1.0" encoding="UTF-8"?>
<p>Most patients with COVID-19 are being treated with Oseltamivir, despite some recent Cochrane reviews questioning its effectiveness in the management of influenza. Oseltamivir has been shown to result in small clinically relevant effects, with a remarkable occurrence of side effects. Data concerning Peramivir are even more limited, with few randomized clinical trials (RCTs) available, thus hindering a comparison between the two neuraminidase inhibitors. Moreover, in-vitro testing assays have failed to show the inhibition of cytopathic effects of SARS-CoV [
 <xref rid="B2-ijerph-17-03176" ref-type="bibr">2</xref>], demonstrating, on the contrary, the efficacy of some commercially available interferons. However, to date, these have been less utilized for the clinical management of patients with COVID-19. 
</p>
